Co-relation of HIV, DM and Tobacco Habited in MDR-TB Suspected Patient

Dipali Gavali*, Binita Aring, Summiya Mullan and Akhlah Ahemad

Department Microbiology, Near TB Hospital, Vikas Gruh Road, Jamnagar, 361008, India

*Corresponding author

Abstract

India is one of the high burden TB countries in the world. Antibiotic resistance is a growing problem in multiple drug-resistance tuberculosis infections. MDR-TB and XDR-TB outbreaks have almost invariably been linked with HIV infection, resulting in exceptionally high patient mortality and highlighting the urgent need for rapid diagnosis and intervention in vulnerable populations. DM is a well-known risk factor for TB, and the epidemics of tobacco smoking and tuberculosis (TB) are colliding, and increasing evidence showed smoking was associated with an increased risk of active TB. Co-relation of HIV, DM and Tobacco habited in MDR-TB suspected patient. A retrospective study was conducted in the TB culture and DST laboratory, Department of Microbiology, from May 2017 to January 2018. We received 585 sputum sample of suspected tuberculosis during study period, 466 were culture Positive, 15 (3%) were Human Immunodeficiency Virus infected, 19 (4%) were Diabetes Mellitus, and 4 (1%) were Tobacco Habited. Conclusion: Prevalence of HIV coinfection with MDR-TB was found to be high among TB patients. It would be appropriate to screen all the TB patients for HIV coinfection apart from their sputa examined for drug resistant tuberculosis, especially in HIV high prevalent states.

Keywords: Co-relation, HIV, DM and tobacco habited, MDR-TB

Accepted: 04 January 2019
Available Online: 10 February 2019

Introduction

Robert Koch isolated the tubercle bacillus in 1882 and proves its role in Tuberculosis. Tuberculosis is a disease caused by Mycobacterium Tuberculosis (MTB). Mycobacteria are non-motile, non-sporing, non-capsulated, weakly gram positive, straight and slightly curved rod shapes bacteria which are obligate aerobes or microaerophilic. Mycobacterium transmitted by inhalation of droplets nuclei generated by cough and sneezing. The Diseases has a high prevalence in India, accounting for one fourth of the Tuberculosis (TB) cases in the world. India is one of the high burden TB countries in the world. According to the WHO Tuberculosis report 2014, there were 9 million incidence cases of TB globally. India having a share of 24% of the global burden. Tuberculosis is the second-most common cause of death from infectious diseases after those due to HIV/AIDS.

Treatment of tuberculosis involves first and second-line anti-tuberculous drugs for drug susceptible and drug resistant cases respectively. During recent years there has been emergence of resistance to first-line TB drugs. Drug resistance in MTB develops by the selective growth of resistant mutants. Antibiotic resistance is a growing problem in
multiple drug-resistance tuberculosis infections. Primary resistance occurs when a person becomes infected with a resistance strain of tuberculosis, but a person with fully susceptible tuberculosis may develop secondary (acquired) resistance during therapy because of inadequate treatment, not taking the prescribed regime appropriately (lack of compliance), or using low-quality medications.\[3\]

Multidrug Resistant Tuberculosis (MDR-TB) is defined when TB bacilli become resistant to both isoniazid and rifampicin or are mono-resistant to rifampicin. Pre-Extensively Drug-Resistant Tuberculosis (Pre XDR-TB) is defined as resistance to rifampicin and/or isoniazid with additional resistance to second-line drugs i.e. to any Fluoroquinolone (FQ), or to at least one of the three injectable second-line drugs [Amikacin, Kanamycin, and Capreomycin (AM)]. Thus Pre XDR-TB consists of two subgroups i.e. 1) MDR-TB with FQ resistance [Pre XDR-TB (FQ)], 2) MDR-TB with AM resistance [Pre XDR-TB (AM)]. Extensively Drug-Resistant Tuberculosis (XDR-TB) is defined as resistance to rifampicin and/or isoniazid with additional resistance to second-line drugs i.e. to any FQ, and to at least one of the three injectable second-line drugs (AM).

World Health Organisation had estimated about 480000 MDR-TB cases in 2014 out of which only 123000 were detected. About 110000 patients of MDR-TB were put on treatment [4]. Of these around 24000 cases of MDR-TB were diagnosed and initiated on therapy in India.[11] World Health Organization (WHO) recommends baseline testing for FQ and AM only among the second-line drugs due to availability of standardised tests and as these two groups of drugs are an important part of MDR-TB treatment regimens across the globe. Subsequent transmission of resistant bacilli is facilitated by inadequate infection control, especially in congregate settings. MDR-TB and XDR-TB outbreaks have almost invariably been linked with HIV infection [5,6], resulting in exceptionally high patient mortality and highlighting the urgent need for rapid diagnosis and intervention in vulnerable populations.

DM is a well-known risk factor for TB. It increases the risk of developing active TB by a factor of 2–3 compared with the normal population[7]. There are also reports of DM patients with TB being more likely to develop drug-resistant TB[10,11], although the numbers of patients reported in these studies are small, and there is little information about whether DM, duration of disease and control of DM have any association with drug-resistant TB.

The epidemics of tobacco smoking and tuberculosis (TB) are colliding, and increasing evidence showed smoking was associated with an increased risk of active TB. An understanding of the epidemiological relationship between smoking and tuberculosis is important because both smoking and tuberculosis cause extensive morbidity and mortality worldwide. Compared with those who have never smoked, it is estimated that people who smoke have approximately twice the risk of both Mycobacterium tuberculosis infection[12] and active tuberculosis.[13]

Becton, Dickinson and Company (BD) developed a new system called Mycobacteria Growth Indicator Tube (MGIT™), which is non-radiometric and offers the rapid, sensitive and reliable methods of testing as the BACTEC 460 TB System. BBL MGIT™ System is the manual system while BACTEC MGIT 960 (MGIT 960) is the fully automatic system for detection of mycobacterial growth and drug susceptibility testing of M. tuberculosis.[8,9]
In our study, we aimed to find the prevalence of Pre XDR-TB and XDR-TB amongst newly diagnosed cases of pulmonary MDR-TB who had never been previously treated with second-line drugs and with co-infection/comorbidities like HIV-TB, DM-TB and tobacco habited-TB by using of BACTEC MGIT 960 (MGIT 960) instrument.

**Aims and Objectives**

We studied the Co-relation of HIV, DM and Tobacco habited in MDR-TB suspected patient.

**Patients were grouped in to**

1. MDR-TB with HIV, DM and Tobacco Habited
2. Pre XDR -TB with HIV, DM and Tobacco Habited
3. XDR-TB HIV, DM and Tobacco Habited

The final data was reported as prevalence of MDR-TB, Pre XDR-TB and XDR-TB in HIV, DM and Tobacco habited patient cases of pulmonary MDR-TB patient.

**Materials and Methods**

A retrospective study was conducted in the TB culture and DST laboratory, Department of Microbiology, in our Hospital, From May 2017 to January 2018.According to History of Human Immunodeficiency virus (HIV), Diabetes (DM) and Tobacco habited we had divided the patient. There were 2 sputum samples, one spot supervised and one early morning collected in sterile screw cap wide mouth falcon tube and transported from various centers to TB culture-DST laboratory by courier with cold chain maintained. All sputum samples were processed following the standard NALC-NaOH method for digestion, decontamination, and concentration\[14,15\]. The concentrated sediment was resuspended in about 2 to 3 ml phosphate buffer (pH 6.8) and mixed thoroughly. Use the resuspended pellet for making smears and for inoculation of MGIT tubes and other media, than according to result follow the direct microscopy, culture and subculture. The use of BACTEC MGIT 960 drug susceptibility testing was done and according to the sensitivity of drug they divided in to MDR-TB, Pre -XDR TB and XDR-TB. We performs second line drug susceptibility testing (Moxifloxacin, Levofloxacin, Amikacin and kanamycin)

**Principle of the BACTECTM MGIT™ 960 System**

The MGIT (Mycobacteria Growth Indicator Tube) consists of liquid broth medium that is known to yield better recovery and faster growth of mycobacteria. MGIT tube contains an oxygen-quenched fluorochrome, tris 4, 7-diphenyl-1, 10-phenothroline ruthenium chloride pentahydrate, embedded in silicone at the bottom of the tube. During bacterial growth within the tube, the free oxygen is utilized and is replaced with carbon dioxide. With depletion of free oxygen, the fluorochrome is no longer inhibited, resulting in fluorescence within the MGIT tube when visualized under UV light. The intensity of fluorescence is directly proportional to the extent of oxygen depletion.

If the test drug is active against the isolated mycobacteria, it will inhibit the growth and thus there will be suppression of fluorescence, while the growth control will grow uninhibited and will have increasing fluorescence.

Growth is monitored by the BACTEC 960 instrument which automatically interprets results as susceptible or resistant. Record “Susceptible (S)”, “Resistant (R) ”, or “Test Failed (TF)” on the internal lab worksheet/book and the lab requisition form
(if applicable). Also, keep the MGIT printouts for all DST results with the patient records.

**Data collection**

We received the sample from the various district for the drug susceptibility testing so, they send the history of the patient like Treatment history, HIV, DM, Tobacco Habits, Alcohol abuse, and gene xpert result for rifampicin resistance.

According to this we study on correlation of HIV-TB, DM-TB and Tobacco-TB in various group of TB Like MDR-TB, Pre XDR-TB and XDR-TB.

**Results and Discussion**

We received 585 sputum sample of suspected tuberculosis during study period, 466 were culture Positive. Out of 466 culture positive sputum samples of pulmonary tuberculosis, 15 (3%) were Human Immunodeficiency Virus (HIV) infected of which 11 had MDR-TB, 2 had Pre XDR-TB and 2 had XDR-TB (Table 1).

19 (4%) were Diabetes Mellitus (DM) of which 12 had MDR-TB, 6 had Pre XDR-TB and 1 had XDR-TB (Table 2).

4 (1%) were Tobacco Habited of which 1 had MDR-TB, 2 had Pre XDR-TB and 1 had XDR-TB.

**Table.1 Shows HIV Infected MDR-TB patients**

<table>
<thead>
<tr>
<th>Category</th>
<th>MDR [No. of Patient]</th>
<th>Pre XDR TB [No. of Patient]</th>
<th>XDR [No. of Patient]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>9</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Female</td>
<td>2</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

In table 1 we can see from above 15 were HIV Infected MDR TB patients of which 11 had MDR-TB, 2 had Pre XDR-TB [FQ], 2 had XDR-TB.

**Graph.1 HIV Infected MDR TB patients**
Table 2 Shows diabetes MDR-TB patients

<table>
<thead>
<tr>
<th>Category</th>
<th>MDR [No. of Patient]</th>
<th>Pre XDR TB [No. of Patient]</th>
<th>XDR [No. of Patient]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>11</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Female</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

In table 2 we can see from above 19 were Diabetes, 12 had MDR-TB, 6 had Pre XDR-TB (FQ), 1 had XDR-TB.

Graph 2 Diabetic MDR TB patients

Table 3 Shows Tobacco abused MDR-TB patients

<table>
<thead>
<tr>
<th>Category</th>
<th>MDR [No. of Patient]</th>
<th>Pre XDR TB [No. of Patient]</th>
<th>XDR [No. of Patient]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Female</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

In table 3 we can see from above 4 were Tobacco Habited, 1 were MDR-TB, 2 were Pre XDR-TB (FQ), 1 were XDR-TB.

Graph 3 Tobacco habited MDR TB patients
Table 4. Comparison of HIV-TB coinfection among MDR-TB

<table>
<thead>
<tr>
<th>HIV-TB Coinfection [%]</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>27.9</td>
<td>Balaji (2010) [17]</td>
</tr>
<tr>
<td>13.9</td>
<td>Rajasekharan (2009) [18]</td>
</tr>
<tr>
<td>4.42</td>
<td>Deivanayagam (2002) [21]</td>
</tr>
<tr>
<td>4</td>
<td>Sameer Adwani (2016) [16]</td>
</tr>
<tr>
<td>3</td>
<td>Present Study (2017)</td>
</tr>
</tbody>
</table>

We studied common comorbidities of HIV among MDR-TB patients. 15 of our study patients were HIV infected which is approximately 3%.

This is higher than the reported 2009 NACO [24] adult HIV prevalence of 0.31%, though HIV-TB co-infection data reported from India is variable.

A study of Balaji et al., Tamil nadu 2010 [17] was tested for HIV most patients with HIV were not on antiretroviral treatment, and Rajasekharan et al., thoracic medicine, Chennai 2009 [18] conduct study on Prevalence of HIV coinfection with MDR-TB was found to be high among chronic TB patients had reported higher prevalence of 27.9% and 13.9% HIV MDR-TB co-infected patients.

In a study conducted in Deivanayagam et al., govt. hospital thoracic medicine, Chennai 2002 [21] and Sameer Adwani Mumbai et al., 2016, were HIV seropositivity among MDR-TB was reported as 4.42% and 4% [16] similar with our results.

Table 5. Comparison of correlation of TB-Diabetes among MDR-TB

<table>
<thead>
<tr>
<th>TB -DM Correlation [%]</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>31.6</td>
<td>Fisher- Hoch SP (2008) [19]</td>
</tr>
<tr>
<td>16.6</td>
<td>Fengling Mi (2014) [20]</td>
</tr>
<tr>
<td>11</td>
<td>Sameer Adwani (2016) [16]</td>
</tr>
<tr>
<td>4</td>
<td>Present Study (2017)</td>
</tr>
</tbody>
</table>

In present study Prevalence of TB-diabetes were 19 (4%), this were more lower than World Health Organization, Geneva shows in India Diabetes accounts for 14.8% of pulmonary tuberculosis. [25]

Lower prevalence in our study is due to observed prevalence does not reflect the prevalence in the community since this was a tertiary care centre and in general, referral basis can lead to wide variation in the observed prevalence amongst different centres.

Present study compared with International studies by SP Fisher-Hoch et al., Brownsville USA (2008) on association between tuberculosis (TB) and diabetes is re-emerging with the epidemic of type 2 diabetes (T2DM) reported higher prevalence DM of 31.6% in MDR-TB [19]. Fengling Mi et al., Beijing TB and thoracic tumour research institute, China (2014) study on is resistance to anti-tuberculosis drugs associated with type 2 diabetes mellitus reported the prevalence of DM as 16.6% [20]. Sameer Adwani et al., TNMC and BYL Nair Hospital, Mumbai (2016) [16] reported prevalence of DM of 11% in MDR-TB patients.

Optimal treatment of these conditions is essential with appropriate MDR therapy.

Table 6. Comparison of correlation of TB-Tobacco among MDR-TB

<table>
<thead>
<tr>
<th>Tobacco-TB Correlation [%]</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>28.8</td>
<td>Zhang et al., 2017 [25]</td>
</tr>
<tr>
<td>4.6</td>
<td>Gegia et al., 2014 [22]</td>
</tr>
<tr>
<td>1</td>
<td>Present Study (2017)</td>
</tr>
</tbody>
</table>

In present study prevalence of TB-Tobacco were 4 (1%), this were very lower than World Health Organization, Geneva shows in India 40% of TB burden may be attributed to smoking. [26] At present study we focused on only Pre XDR TB and XDR -TB and also study on DST laboratory sample referred by other districts so, not availability of proper information our study prevalence is lower than other study.

H. Zhang et al., study on a dose- response relationship of smoking with tuberculosis infection, 2017 [23] and M. Gegia et al., study on Tobacco smoking and tuberculosis treatment outcomes, 2014 [22] both study done on tobacco – tuberculosis correlation so, their prevalence were higher than our study.
Present study was done to know the baseline pattern of drug resistance among the pulmonary MDR-TB patients who had not been previously exposed to second line drugs in form of anti-tuberculous therapy. As per WHO recommendations, baseline second-line DST to FQ and AM was studied only.

Total 585 sputum samples, 466 had tuberculosis infection, 293 were Multidrug resistance Tuberculosis, 151 were Pre Extensively drug resistance Tuberculosis and 22 were Extensively drug resistance Tuberculosis (Table 1-6).

In conclusion, we studied the prevalence of Pre XDR-TB and XDR-TB among MDR-TB patients, which were 32.4% and 4.7% respectively. The high prevalence of Pre XDR-TB (FQ) is alarming and of concern in management of MDR-TB. Indiscriminate use of fluoroquinolone should be stopped. These patients should be evaluated for the presence of comorbidities like HIV and DM and treated appropriately.

Prevalence of HIV coinfection with MDR-TB was found to be high among TB patients. It would be appropriate to screen all the TB patients for HIV coinfection apart from their sputa examined for drug resistant tuberculosis, especially in HIV high prevalent states.

For Diabetes -TB Correlation prospective research is needed on the association between DM and drug-resistant TB, and this research will need to factor in other determinants of drug resistance in order to better understand the interactions between the two diseases.

Tobacco smoking increases the risk of a poor treatment outcome. Our findings support that cigarette smoking was independently associated with increased risk of TB infection. More attention should be attached to smokers, especially elderly smokers. In addition, active case finding among populations with specific risks such as smokers, close contacts, diabetes should be strengthened as well.

References


Kent PT, Kubica GP. 1985. Public health microbiology, a guide for the level III laboratory. Centers for Disease Control, Division of Laboratory Training and Consultation, Atlanta, GA.


World Health Organization (2016).” The sixteenth global report on tuberculosis” (PDF), Geneva shows in


How to cite this article: